<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="3201">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04381819</url>
  </required_header>
  <id_info>
    <org_study_id>20-04072</org_study_id>
    <nct_id>NCT04381819</nct_id>
  </id_info>
  <brief_title>Norwegian SARS-CoV-2 Study - Virological, Clinical and Immunological Characterisation of COVID-19</brief_title>
  <official_title>Norwegian SARS-CoV-2 Study - Virological, Clinical and Immunological Characterisation of Inpatients During the COVID-19 Outbreak: A Prospective Cohort Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Oslo University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University Hospital, Akershus</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Vestre Viken Hospital Trust</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Østfold Hospital Trust</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Haukeland University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital of North Norway</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>St. Olavs Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Oslo University Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Oslo University Hospital has initiated an observational study on hospitalised patients with
      confirmed COVID-19, the infection caused by Severe Acute Respiratory Syndrome Coronavirus
      type 2 (SARS-CoV-2).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Infectious disease is the single biggest cause of death worldwide. New infectious agents,
      such as the SARS-CoV-2, require investigation to understand pathogen biology and pathogenesis
      in the host. In order to develop a mechanistic understanding of disease processes, such that
      risk factors for severe illness can be identified and treatments can be developed, it is
      necessary to understand pathogen characteristics associated with virulence, the replication
      dynamics and in-host evolution of the pathogen, the dynamics of the host response, the
      pharmacology of antimicrobial or host directed therapies, the transmission dynamics, and
      factors underlying individual susceptibility.

      At Oslo University Hospital, an observational study on the newly discovered emerging SARS-
      CoV-2, the coronavirus that causes COVID-19 infection has started. The study has been
      approved by the Regional Ethics Committee, so that inclusion of confirmed COVID-19 cases
      admitted at the hospital can start immediately including the first patients needing
      hospitalisation. The plan is to include more hospitals in other parts of Norway, starting
      with inclusion of Akershus University Hospital, Vestre Viken Drammen Hospital and Østfold
      Hospital. The study is anticipated to provide much needed data on the course of the COVID-19
      infection, as well as generating knowledge about the virus and its transmission.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 2, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">February 28, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Death</measure>
    <time_frame>From date of randomization until the date of death from any cause assessed up to 3 months.</time_frame>
    <description>Fatal outcome from COVID-19</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Recovery from COVID-19</measure>
    <time_frame>From date of randomization until the date of recovery from COVID-19 symptoms assessed up to 3 months.</time_frame>
    <description>Resolved infection</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Progression to ICU care or ventilation</measure>
    <time_frame>30 days</time_frame>
    <description>Percentage of patients requiring intensive care admission or ventilation</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clearance of SARS-CoV-2 from respiratory specimen</measure>
    <time_frame>The number of calendar days from date of PCR positive test (counted as 1 day) in respiratory specimen until date of such test first become negative in the respiratory specimen assessed up to 3 months</time_frame>
    <description>The change in(clearance of) viral RNA measured by polymerase chain reaction assay (PCR) test at days 1, 3, 8,14 and 90 days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immune response to COVID-19</measure>
    <time_frame>From date of randomization until the date of clinical follow-up assessed up to 3 months.</time_frame>
    <description>Cell-mediated and humoral immunity</description>
  </secondary_outcome>
  <enrollment type="Anticipated">1000</enrollment>
  <condition>SARS Virus</condition>
  <condition>Severe Acute Respiratory Syndrome</condition>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>SARS-CoV-2 PCR</intervention_name>
    <description>SARS-CoV-2 E gene</description>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Respiratory secretions, blood, urine, stool, cerebrospinal fluid
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients admitted to Oslo University Hospital, Vestre Viken Drammen Hospital, Akershus
        University Hospital or Østfold Hospital Kalnes will be recruited consecutively after
        testing positive for SARS-CoV-2
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Confirmed COVID-19 by screening of SARS-CoV-2 E-gene

        Exclusion Criteria:

          -  Refusal of consent by patient or closest relative
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Fredrik G Müller, Professor</last_name>
    <role>Study Director</role>
    <affiliation>University of Oslo</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Susanne G Dudman, Professor</last_name>
    <role>Study Chair</role>
    <affiliation>University of Oslo</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jan C Holter, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Oslo University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jan C Holter, PhD</last_name>
    <phone>+4791195761</phone>
    <phone_ext>+4723071155</phone_ext>
    <email>jacaho@ous-hf.no</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Susanne G Dudman, PhD</last_name>
    <phone>+4723071155</phone>
    <phone_ext>+4723071155</phone_ext>
    <email>Susanne.Dudman@ous-hf.no</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Vestre Viken Drammen Hospital</name>
      <address>
        <city>Drammen</city>
        <state>Viken</state>
        <zip>3000</zip>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lars Heggelund, PhD</last_name>
    </contact>
    <contact_backup>
      <email>Lars.Heggelund@vestreviken.no</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Haukeland University Hospital</name>
      <address>
        <city>Bergen</city>
        <zip>5021</zip>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bjørn Blomberg, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Østfold Hospital Trust</name>
      <address>
        <city>Fredrikstad</city>
        <zip>1714</zip>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jonas Bergan, phd</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Akershus University Hospital</name>
      <address>
        <city>Lørenskog</city>
        <zip>1478</zip>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christian Prebensen, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Oslo University Hospital</name>
      <address>
        <city>Oslo</city>
        <zip>0424</zip>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jan C Holter, PhD</last_name>
      <phone>+4791195761</phone>
      <phone_ext>+4791195761</phone_ext>
      <email>jacaho@ous-hf.no</email>
    </contact>
    <contact_backup>
      <last_name>Susanne G Dudman, Ass.Professor</last_name>
      <phone>+4791195761</phone>
      <phone_ext>+4791195761</phone_ext>
      <email>Susanne.Dudman@ous-hf.no</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>University Hospital North Norway</name>
      <address>
        <city>Tromsø</city>
        <zip>9019</zip>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anders B Kildal, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>St Olavs Hospital</name>
      <address>
        <city>Trondheim</city>
        <zip>7030</zip>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Erik Solligård, PhD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Norway</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>May 4, 2020</study_first_submitted>
  <study_first_submitted_qc>May 8, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 11, 2020</study_first_posted>
  <last_update_submitted>May 8, 2020</last_update_submitted>
  <last_update_submitted_qc>May 8, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 11, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Oslo University Hospital</investigator_affiliation>
    <investigator_full_name>Jan Cato Holter</investigator_full_name>
    <investigator_title>Project leader, medical doctor, PhD</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Severe Acute Respiratory Syndrome</mesh_term>
    <mesh_term>Coronavirus Infections</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

